Empagliflozin in acute Myocardial Infarction: the EMMY trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36036746/
doi: 10.1093/eurheartj/ehac494. Online ahead of print. 1 Medical University of Graz, Department of Internal Medicine, Division of Cardiology, Graz, Austria. 2 Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology, Graz, Austria. 3 Medical University of Graz, Interdisciplinary Metabolic Medicine Trials Unit, Graz, Austria.
Conclusions: In patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters.